For over 35 years, we have been committed to providing innovative solutions to medical laboratories, contributing to the constant improvement of medicine and diagnostics.
In 2021, i2a obtained an investment from the healthcare specialist investor, Apposite Capital, thus marking a new era in its development. This strategic partnership has allowed us to expand geographically, invest in research and development, and recruit c.30 additional employees.
We are proud of our collaboration with Apposite Capital, which opens new opportunities for i2a. By joining forces, we are better equipped to respond to public health challenges, providing innovative and sustainable solutions to combat antibiotic resistance.
This partnership demonstrates our continued commitment to innovation and excellence in the field of medical microbiology.
